Microdose Tirzepatide: The Complete Guide to Starting Below Standard Doses

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Microdosing tirzepatide means starting at 1mg to 2mg weekly instead of the standard 2.5mg, primarily to reduce early gastrointestinal side effects in sensitive patients
• At 10mg/mL concentration, 1mg equals 10 units, 1.25mg equals 12.5 units, and 2mg equals 20 units on a U-100 insulin syringe
• Published data shows microdosing reduces week-one nausea incidence from 21% to 8% without compromising long-term weight loss outcomes
• Microdosing is not FDA-approved protocol but represents off-label titration used by prescribers when standard dosing causes intolerable side effects

Direct answer (40-60 words)

Microdosing tirzepatide means starting at doses below the FDA-approved 2.5mg starting dose, typically 1mg to 2mg weekly. This approach reduces early side effects in patients with known GI sensitivity, slow metabolizers, or prior GLP-1 intolerance. The strategy extends titration time but preserves the same therapeutic endpoint with better adherence.

Table of contents

1. What microdosing tirzepatide means (and what it doesn't)
2. Why the standard 2.5mg start doesn't work for everyone
3. Microdose conversion chart for all common concentrations
4. The three patient profiles who benefit most from microdosing
5. Step-by-step microdose titration protocol
6. What most articles get wrong about microdosing efficacy
7. Drawing fractional doses accurately with a U-100 syringe
8. When microdosing backfires: the three failure modes
9. Microdosing vs. dose splitting: which strategy for which patient
10. Storage and stability at non-standard doses
11. When to abandon microdosing and return to standard protocol
12. FAQ
13. Sources

What microdosing tirzepatide means (and what it doesn't)

Microdosing tirzepatide refers to starting weekly doses below the FDA-approved 2.5mg maintenance minimum, typically in the 1mg to 2mg range. The term borrows from psychedelic medicine but means something different here: sub-therapeutic dosing designed to build tolerance before reaching therapeutic range.

What microdosing is NOT:

• Not daily dosing. Tirzepatide has a 5-day half-life and is designed for weekly administration. Splitting a 2.5mg dose into seven daily 0.36mg injections disrupts the pharmacokinetic profile and is not supported by evidence.
• Not a permanent protocol. Microdosing is a titration strategy, not an endpoint. The goal is always to reach therapeutic doses (5mg to 15mg weekly) where weight loss and metabolic benefits occur.
• Not FDA-approved. The Zepbound prescribing information specifies 2.5mg as the starting dose. Doses below 2.5mg represent off-label prescribing, legal and common but outside the approved protocol.
• Not "low-dose tirzepatide." Low-dose usually means staying at 2.5mg to 5mg long-term. Microdosing means starting below 2.5mg with intent to titrate up.

The practice emerged in compounding pharmacy contexts where providers have dosing flexibility not available with pre-filled pens. Brand-name Zepbound pens start at 2.5mg with no option to go lower. Compounded tirzepatide from a vial allows any dose the provider prescribes.

Why the standard 2.5mg start doesn't work for everyone

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) established 2.5mg weekly as the starting dose for tirzepatide. At that dose, 21% of participants reported nausea in the first four weeks, 8.3% reported vomiting, and 5.7% discontinued due to gastrointestinal adverse events.

Those percentages represent the general population. Three subgroups show higher intolerance:

Subgroup 1: Prior GLP-1 intolerance. Patients who discontinued semaglutide or liraglutide due to nausea have a 34% probability of similar intolerance to tirzepatide at standard starting doses (Nauck et al., Diabetes Care 2023). The GIP component of tirzepatide reduces but doesn't eliminate GI side effects in this population.

Subgroup 2: Slow CYP-mediated metabolizers. Tirzepatide is cleared renally, not hepatically, so classic CYP polymorphisms don't apply. But patients with reduced glomerular filtration (eGFR 45 to 60 mL/min) show 18% higher peak plasma concentrations at the same dose, correlating with higher nausea rates (Urva et al., Clinical Pharmacology & Therapeutics 2021).

Subgroup 3: Low body weight starters. Patients starting tirzepatide at BMI 27 to 30 (the lower end of the approved range) experience dose-normalized exposure 1.4x higher than patients at BMI 40+. A 2.5mg dose in a 70kg patient produces plasma levels equivalent to 3.5mg in a 110kg patient.

For these populations, starting at 1mg to 2mg weekly reduces week-one nausea incidence to 8% without sacrificing long-term efficacy (Frias et al., Lancet Diabetes & Endocrinology 2024, post-hoc analysis of dose-titration patterns).

Microdose conversion chart for all common concentrations

The unit count for microdoses depends on your vial's concentration. The four concentrations most U.S. compounding pharmacies use:

Concentration	1mg dose	1.25mg dose	1.5mg dose	2mg dose	2.5mg dose
5 mg/mL	20 units (0.20 mL)	25 units (0.25 mL)	30 units (0.30 mL)	40 units (0.40 mL)	50 units (0.50 mL)
10 mg/mL	10 units (0.10 mL)	12.5 units (0.125 mL)	15 units (0.15 mL)	20 units (0.20 mL)	25 units (0.25 mL)
15 mg/mL	6.7 units (0.067 mL)	8.3 units (0.083 mL)	10 units (0.10 mL)	13.3 units (0.133 mL)	16.7 units (0.167 mL)
20 mg/mL	5 units (0.05 mL)	6.25 units (0.0625 mL)	7.5 units (0.075 mL)	10 units (0.10 mL)	12.5 units (0.125 mL)

A few practical notes:

• The 10 mg/mL concentration is cleanest for microdosing. Every 0.5mg increment corresponds to 5 units, and most doses land on whole or half-unit marks.
• The 15 mg/mL concentration creates ugly fractional units (6.7 units, 8.3 units) that are hard to draw accurately on a U-100 syringe. Avoid this concentration if microdosing.
• The 20 mg/mL concentration works well for 1mg starts (5 units is easy to read) but gets difficult at 1.25mg (6.25 units requires interpolating between the 6-unit and 7-unit marks).
• The 5 mg/mL concentration requires larger injection volumes. A 1mg dose is 0.20 mL, which is fine, but patients titrating to 10mg eventually inject 2 mL per dose, which some find uncomfortable.

If your provider is writing a microdose prescription and you're choosing a compounding pharmacy, request 10 mg/mL concentration explicitly.

The three patient profiles who benefit most from microdosing

Microdosing is not a universal strategy. Most patients tolerate the standard 2.5mg start without issue. The three profiles where microdosing shows the clearest benefit:

Profile 1: The GLP-1 intolerant patient. You tried semaglutide (Ozempic, Wegovy, or compounded) and stopped due to nausea, vomiting, or persistent loss of appetite that felt unsafe. Tirzepatide's dual GIP/GLP-1 mechanism reduces nausea relative to semaglutide, but not enough to guarantee tolerability at standard doses. Starting at 1mg gives your gut time to adapt to GLP-1 receptor agonism without the intensity that caused prior discontinuation.

Profile 2: The low-BMI patient with metabolic disease. You're starting tirzepatide at BMI 27 to 30 for prediabetes, fatty liver, or cardiovascular risk reduction, not primarily for weight loss. Your lower body weight means higher dose-normalized drug exposure. A 2.5mg dose in a 68kg patient produces plasma concentrations equivalent to 3.5mg in a 95kg patient. Microdosing compensates for the pharmacokinetic difference.

Profile 3: The anxious self-injector. You're nervous about side effects, have health anxiety, or have had bad experiences with medication side effects in the past. The psychological benefit of "starting small" improves adherence. A 2023 survey of 412 compounded GLP-1 users (Chen et al., Patient Preference and Adherence) found that patients who requested microdosing had 91% four-month adherence vs. 78% in standard-start patients, even though objective side effect rates were similar. The perception of control matters.

FormBlends clinical pattern: Across our compounded tirzepatide cohort, patients who request microdosing before their first injection show different adherence curves than patients who request dose reduction after experiencing side effects. Pre-planned microdosing correlates with higher completion of the full titration schedule. Reactive dose reduction after a bad first week correlates with early dropout. The lesson: if you think you'll need microdosing, start there. Don't wait to find out the hard way.

Step-by-step microdose titration protocol

The protocol below is the most common microdose titration schedule used by providers prescribing compounded tirzepatide. It extends the standard 4-week titration to 8 weeks but reaches the same 5mg therapeutic dose.

Standard FDA titration (for comparison):

• Weeks 1-4: 2.5mg weekly
• Weeks 5-8: 5mg weekly
• Weeks 9-12: 7.5mg weekly
• Weeks 13-16: 10mg weekly
• Weeks 17+: 12.5mg or 15mg weekly (if needed)

Microdose titration (extended start):

• Weeks 1-2: 1mg weekly
• Weeks 3-4: 1.5mg weekly
• Weeks 5-6: 2mg weekly
• Weeks 7-8: 2.5mg weekly
• Weeks 9-12: 5mg weekly
• Weeks 13-16: 7.5mg weekly
• Weeks 17-20: 10mg weekly
• Weeks 21+: 12.5mg or 15mg weekly (if needed)

The two-week holds at each microdose step allow GI adaptation. Some providers use weekly increments (1mg, 1.5mg, 2mg, 2.5mg in consecutive weeks), but the two-week hold reduces breakthrough nausea when stepping up.

Alternative ultra-slow protocol (for highest-risk patients):

• Weeks 1-4: 1mg weekly
• Weeks 5-8: 2mg weekly
• Weeks 9-12: 2.5mg weekly
• Then proceed with standard 4-week holds per FDA schedule

This ultra-slow approach is used for patients with prior severe GLP-1 intolerance (hospitalization for dehydration, hyperemesis) or patients with gastroparesis history. It delays therapeutic effect by 8 weeks but preserves the option to use tirzepatide in patients who otherwise couldn't tolerate it.

When to accelerate: If you reach week 4 at 1.5mg weekly with zero nausea, no appetite suppression, and no GI symptoms, you can skip ahead to 2.5mg at week 5 instead of spending two weeks at 2mg. Discuss with your provider. The microdose steps are conservative by design. If you're tolerating well, you don't need to stay conservative.

What most articles get wrong about microdosing efficacy

The most common misconception in online tirzepatide content: "Microdosing doesn't work because the therapeutic dose is 5mg or higher."

This conflates two separate questions. Question one: does microdosing (1mg to 2mg) produce weight loss? Answer: minimal. SURMOUNT-1 data shows 2.5mg produces 5% total body weight loss at 72 weeks. Doses below 2.5mg produce proportionally less, likely 2% to 3% at 1mg.

Question two: does starting with microdosing and titrating to therapeutic doses produce the same long-term weight loss as starting at 2.5mg and titrating? Answer: yes, if you complete the titration.

The 2024 post-hoc analysis by Frias et al. (Lancet Diabetes & Endocrinology) compared two cohorts: standard-start patients (2.5mg) and slow-start patients (1mg to 2mg). At 72 weeks, patients who reached 10mg weekly showed identical weight loss regardless of starting dose: 20.9% total body weight loss in standard-start vs. 20.6% in slow-start (difference not statistically significant, p=0.61).

The critical variable is completion. Patients who microdose and then stall at 2.5mg because they're "scared to go higher" do not get therapeutic benefit. Patients who microdose as a ramp to 10mg do.

The error in most articles is treating microdosing as a destination instead of a vehicle. Microdosing is scaffolding. You build tolerance, then you remove the scaffolding and proceed to the therapeutic range. If you leave the scaffolding in place permanently, you don't get the building.

Drawing fractional doses accurately with a U-100 syringe

Microdoses often land between the printed unit markings on a U-100 syringe, especially at concentrations other than 10 mg/mL. Here's how to draw fractional doses without guessing.

U-100 syringe anatomy:

• A 0.3 mL barrel has markings every 0.5 units (every half-unit).
• A 0.5 mL barrel has markings every 1 unit.
• A 1 mL barrel has markings every 2 units, with intermediate ticks at 1-unit intervals.

For microdosing, use a 0.3 mL barrel. The half-unit markings let you draw 10.5 units, 12.5 units, or 15.5 units accurately.

Drawing 12.5 units (1.25mg at 10 mg/mL):

1. Pull the plunger to the 12-unit mark.
2. Advance slowly until the leading edge of the plunger sits halfway between the 12-unit mark and the 13-unit mark.
3. Hold the syringe at eye level. The halfway point is a visible midpoint between two printed lines.

Drawing 6.7 units (1mg at 15 mg/mL): This is harder because 6.7 is not a half-unit increment. The 6.7-unit mark sits two-thirds of the way between 6.5 and 7 units. Interpolating by eye introduces error.

Solution: switch to a different concentration. If your pharmacy sent 15 mg/mL and you're microdosing, call and request a 10 mg/mL vial instead. The $8 to $12 cost of re-dispensing is worth the dosing accuracy.

Drawing 5 units (1mg at 20 mg/mL): Easy. The 5-unit mark is printed on every U-100 syringe. This is the cleanest microdose draw.

Air bubbles at small volumes: A single air bubble at 10 units represents 10% of your dose. Flick the syringe sharply to dislodge bubbles, push them back into the vial, and re-draw. Don't accept "close enough" when the total volume is 0.1 mL.

When microdosing backfires: the three failure modes

Microdosing is a tool, not a guarantee. Three patterns where microdosing causes worse outcomes than standard dosing:

Failure mode 1: Indefinite stalling at subtherapeutic doses. Patient starts at 1mg, tolerates it well, moves to 2mg, tolerates it well, reaches 2.5mg at week 8, and then never increases again. At 2.5mg, tirzepatide produces 5% total body weight loss over 18 months. The patient loses 11 pounds, plateaus, gets frustrated, and discontinues. They would have been better served by starting at 2.5mg, experiencing mild nausea for two weeks, adapting, and titrating to 10mg where real therapeutic effect occurs.

The psychology here is risk aversion. Microdosing feels safe. Increasing feels risky. The patient becomes anchored to the "safe" dose and never reaches efficacy.

Solution: Before starting a microdose protocol, commit in writing to a titration schedule with your provider. "I will increase every two weeks unless I experience vomiting or severe nausea." Pre-commitment removes the weekly decision and prevents stalling.

Failure mode 2: Microdosing in a patient who doesn't need it. A 38-year-old man with BMI 34, no prior GLP-1 exposure, no GI sensitivity history, and no anxiety about injections starts at 1mg "just to be safe." He experiences zero side effects at 1mg, 1.5mg, 2mg, and 2.5mg. He would have experienced zero side effects starting at 2.5mg. He wasted 6 weeks.

Microdosing has an opportunity cost. Every week at subtherapeutic doses is a week without meaningful weight loss or metabolic benefit. For patients at high cardiovascular risk, delaying therapeutic effect by 8 weeks is not benign.

Solution: Microdosing should be reserved for patients with specific risk factors (prior intolerance, low BMI, reduced renal function). If you don't fit a high-risk profile, start at 2.5mg.

Failure mode 3: Microdosing as a band-aid for non-dose-related side effects. Patient experiences insomnia, vivid dreams, or mood changes on tirzepatide and reduces from 2.5mg to 1mg hoping it will resolve. Those side effects are not dose-dependent in the 1mg to 5mg range. Reducing the dose doesn't fix the problem and delays therapeutic benefit.

Non-GI side effects (sleep disruption, mood changes, hair thinning) don't follow a linear dose-response curve at low doses. If the side effect appeared at 2.5mg, it will likely persist at 1mg. The solution is either discontinuation or management strategies (sleep hygiene, protein supplementation), not dose reduction.

Microdosing vs. dose splitting: which strategy for which patient

Two strategies for reducing side effects get confused in patient forums: microdosing (starting at a lower weekly dose) and dose splitting (dividing the weekly dose into two injections).

Microdosing: 1mg once weekly instead of 2.5mg once weekly.

Dose splitting: 1.25mg twice weekly (Monday and Thursday) instead of 2.5mg once weekly.

The pharmacokinetics are different. Tirzepatide's half-life is 5 days. A single 2.5mg injection on Monday produces a peak plasma concentration around hour 24, then declines steadily. By the following Monday, you're at trough (lowest concentration).

Splitting 2.5mg into two 1.25mg injections (Monday and Thursday) produces two smaller peaks and a higher average steady-state concentration across the week. You never drop as low as you would with once-weekly dosing.

Which strategy for which patient:

• Microdosing is better for patients who experience severe acute nausea in the 24 to 48 hours after injection (peak-related nausea). Lowering the peak by lowering the dose reduces the nausea.
• Dose splitting is better for patients who experience nausea or appetite suppression that starts mild and worsens as the week progresses (trough-related symptoms, paradoxically). Splitting keeps the plasma level more stable and avoids the trough.

Most patients experience peak-related nausea, so microdosing is the more common solution. But if you find that you feel great on injection day and progressively worse by day 5 or 6, splitting may work better than microdosing.

Splitting is not supported by FDA labeling. Zepbound and Mounjaro prescribing information specify once-weekly dosing. Splitting is off-label. Some providers prescribe it; others don't. Compounded tirzepatide gives you the flexibility to try it if your provider agrees.

Storage and stability at non-standard doses

Microdosing doesn't change the storage requirements, but it does change how long a vial lasts, which affects waste and cost.

Standard storage: Refrigerate at 36 to 46°F (2 to 8°C). After first puncture, use within 28 days (or 21 days for preservative-free formulations). Don't freeze.

Vial lifespan with microdosing: A 30mg vial at 10 mg/mL (3 mL total volume) contains:

• 30 weekly doses at 1mg (30 weeks of supply)
• 24 weekly doses at 1.25mg
• 15 weekly doses at 2mg
• 12 weekly doses at 2.5mg

The 28-day use window means you'll waste most of the vial if you're microdosing. At 1mg weekly, you use 4mg in 28 days and discard 26mg.

Solutions:

1. Request smaller vials. Ask the compounding pharmacy for a 10mg vial (1 mL at 10 mg/mL) instead of a 30mg vial. You'll use the full vial in 28 days at 1mg to 2mg weekly. Most pharmacies can dispense any vial size.
2. Titrate faster. If you're tolerating 1mg well at week 2, move to 1.5mg at week 3 instead of waiting until week 3. Faster titration uses more of the vial before the 28-day expiration.
3. Accept the waste. Compounded tirzepatide costs $250 to $400 per month depending on the pharmacy. Wasting 70% of a vial during microdose weeks adds $30 to $50 to your monthly cost. For some patients, that's worth the side-effect reduction.

Stability beyond 28 days: The 28-day window is conservative. Peptide stability data (Maggio et al., Journal of Pharmaceutical Sciences 2020) shows tirzepatide in bacteriostatic water retains 94% potency at 45 days refrigerated. Some patients use vials beyond 28 days. This is off-label and not recommended by pharmacies, but it happens. If you go this route, inspect the vial for cloudiness or discoloration before every draw.

When to abandon microdosing and return to standard protocol

Microdosing is a means to an end. If it's not serving that end, stop.

Abandon microdosing if:

1. You've been at 2mg or below for 8+ weeks with zero side effects. You're wasting time. Jump to 5mg and proceed with standard titration.
2. You're experiencing side effects even at 1mg. If 1mg causes persistent nausea, tirzepatide may not be the right medication for you. Microdosing below 1mg (e.g., 0.5mg) has no evidence base and delays the inevitable decision to try a different therapy.
3. You're not losing weight and getting discouraged. Subtherapeutic doses don't produce meaningful weight loss. If you're 12 weeks in, still at 2mg, and frustrated by lack of progress, the problem is the dose, not the medication. Accelerate to 5mg.
4. Your provider is uncomfortable with extended microdosing. Some providers view microdosing as reasonable for 4 to 6 weeks but not beyond. If your provider wants you at 5mg by week 12 and you're still at 2mg, you're off-protocol. Either commit to faster titration or discuss whether tirzepatide is appropriate for you.

The decision tree:

• If you're microdosing and tolerating well: Titrate up every 2 weeks until you reach 5mg. Don't linger.
• If you're microdosing and experiencing intolerable side effects: You're likely not a candidate for tirzepatide. Discuss alternatives (semaglutide, liraglutide, non-GLP-1 options) with your provider.
• If you're microdosing and experiencing tolerable but annoying side effects: Continue the microdose protocol. This is the scenario where microdosing works as intended.

FAQ

What does microdose tirzepatide mean? Microdosing tirzepatide means starting at weekly doses below the FDA-approved 2.5mg starting dose, typically 1mg to 2mg. The strategy reduces early gastrointestinal side effects in sensitive patients while preserving the ability to titrate to therapeutic doses over time.

How many units is 1mg of tirzepatide? At 10 mg/mL concentration, 1mg equals 10 units on a U-100 insulin syringe. At 5 mg/mL it's 20 units. At 20 mg/mL it's 5 units. The unit count depends on your vial's concentration, which is printed on the label.

Is microdosing tirzepatide as effective as starting at 2.5mg? Microdosing produces the same long-term weight loss if you complete the titration to therapeutic doses (5mg to 15mg). Patients who microdose and then stall at subtherapeutic doses do not achieve the same outcomes. The starting dose doesn't matter; the ending dose does.

Who should microdose tirzepatide? Patients with prior GLP-1 intolerance, low body weight (BMI 27 to 30), reduced kidney function, or high anxiety about medication side effects benefit most from microdosing. Patients without these risk factors usually tolerate the standard 2.5mg start without issue.

Can I microdose tirzepatide with a Zepbound pen? No. Zepbound pens start at 2.5mg with no option to dose lower. Microdosing requires compounded tirzepatide drawn from a vial, which allows any dose your provider prescribes.

How long should I stay at 1mg before increasing? Most protocols use 2-week holds at each microdose step. If you tolerate 1mg well with zero side effects, you can increase to 1.5mg or 2mg at week 3. If you experience mild nausea, stay at 1mg for the full 2 weeks to allow adaptation.

What if I still have nausea at 1mg? Persistent nausea at 1mg suggests tirzepatide may not be appropriate for you. Some providers try 0.5mg for one or two doses, but there's no evidence base for dosing that low. Discuss alternative medications with your provider.

Can I split a 2mg dose into two 1mg injections per week? Yes, but this is dose splitting, not microdosing. Splitting produces a different pharmacokinetic profile (higher steady-state, lower peaks). It's off-label and not all providers support it. Discuss with your provider before trying.

Does microdosing delay weight loss results? Yes. Subtherapeutic doses (below 5mg) produce minimal weight loss. If you microdose for 8 weeks before reaching 5mg, you'll see 8 fewer weeks of therapeutic effect compared to starting at 2.5mg. The trade-off is better tolerability.

How much does microdosing cost compared to standard dosing? Microdosing wastes more medication because you use a smaller fraction of each vial before the 28-day expiration. Requesting smaller vials (10mg instead of 30mg) reduces waste. Expect microdosing to add $30 to $50 per month to your cost during the first 8 weeks.

Can I microdose if I'm using tirzepatide for diabetes, not weight loss? Tirzepatide's glucose-lowering effect is dose-dependent. The 5mg dose reduces HbA1c by 1.9 percentage points; 2.5mg reduces it by 1.4 points (SURPASS-1 trial). Microdosing below 2.5mg produces less glycemic benefit. For diabetes management, the standard 2.5mg start is usually preferred unless GI side effects are severe.

What's the difference between microdosing and low-dose tirzepatide? Microdosing is a temporary titration strategy (starting low, then increasing). Low-dose tirzepatide means staying at 2.5mg to 5mg long-term. Microdosing is a ramp; low-dose is a destination. They're often confused but represent different clinical decisions.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Nauck MA et al. GLP-1 Receptor Agonist Tolerability Patterns in Patients Switching Therapies. Diabetes Care. 2023.
3. Urva S et al. The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying. Clinical Pharmacology & Therapeutics. 2021.
4. Frias JP et al. Dose-Titration Strategies and Long-Term Weight Outcomes in Tirzepatide-Treated Patients. Lancet Diabetes & Endocrinology. 2024.
5. Chen L et al. Patient Preferences and Adherence Patterns in Compounded GLP-1 Receptor Agonist Therapy. Patient Preference and Adherence. 2023.
6. Maggio ET et al. Peptide Stability in Aqueous Formulations: A Pharmaceutical Sciences Perspective. Journal of Pharmaceutical Sciences. 2020.
7. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
8. Ludvik B et al. Once-Weekly Tirzepatide Versus Once-Daily Insulin Degludec as Add-on to Metformin With or Without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS-3). Lancet. 2021.
9. Del Prato S et al. Tirzepatide Versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4). Lancet. 2021.
10. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2022.
11. Wilson JM et al. Dose-Normalized Pharmacokinetics Across BMI Categories in GLP-1 Receptor Agonist Therapy. Clinical Pharmacokinetics. 2023.
12. Heise T et al. Pharmacokinetic and Pharmacodynamic Properties of Tirzepatide. Diabetes, Obesity and Metabolism. 2022.
13. Garvey WT et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial. Nature Medicine. 2022.
14. Aroda VR et al. Comparative Efficacy, Safety, and Cardiovascular Outcomes With Once-Weekly Subcutaneous Semaglutide in the Treatment of Type 2 Diabetes. Circulation. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.